Top

Neurological Sciences

Published in:

11-07-2022 | Migraine | Review Article

Ditans: a new prospective for the therapy of migraine attack?

Authors: Giovanna Viticchi, Lorenzo Falsetti, Mauro Silvestrini, Marco Bartolini

Published in: Neurological Sciences | Issue 9/2022

Abstract

Introduction

Migraine attack is characterized by disabling pain and associated symptoms. Triptans represent the “gold standard” therapy, but cardiac subjects have significant limitations for this approach. New drug families are under consideration to expand therapeutic offerings, especially in the presence of contraindications or for non-responsive patients. This review aimed to analyze studies related to the category of “ditans,” with a focus on lasmiditan, which is available for human use.

Materials and methods

We consulted PubMed/MEDLINE, Web of Science, and www.clinicaltrials.gov to find both original and review articles on the mechanism of action of 5-HT1F agonists in migraine, and for randomized, double-blind, placebo-controlled trials (RCTs) on the family of drugs called “ditans,” with a focus on “lasmiditan,” published in the time frame of 01-Jan-2010 to 31-Mar-2022. Only studies conducted in human subjects and published in English were included in this review.

Results

We retrieved four RCTs (named SAMURAI, SPARTAN, GLADIATOR, and CENTURION) and several studies that analyzed the efficacy and safety of lasmiditan. Lasmiditan at increasing doses showed significant improvement in pain and most other troublesome symptoms at 2 h. Adverse events were mild and mainly represented by dizziness, vertigo, drowsiness, and fatigue. No vasoconstrictive effects were described, suggesting the use of ditans as a safe option in chronic cardio- and cerebro-vascular disease.

Discussion

Lasmiditan could be a viable alternative to triptans, although further RCT studies and real-world evidence are needed to better understand its potential and possible adverse events in a larger population.

Kuca B, Silberstein SD, Wietecha L et al (2018) Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology 91:e2222–e2232. https://doi.org/10.1212/WNL.0000000000006641CrossRefPubMedPubMedCentral

Sheftell F, Almas M, Weeks R et al (2010) Quantifying the return of headache in triptan-treated migraineurs: an observational study. Cephalalgia 30:838–846. https://doi.org/10.1177/0333102409354390CrossRefPubMed

Kimball RW, Friedman AP, Vallejo E (1960) Effect of serotonin in migraine patients. Neurology 10:107–111. https://doi.org/10.1212/wnl.10.2.107CrossRefPubMed

Dahlöf C, Maassen Van Den Brink A (2012) Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache 52:707–714. https://doi.org/10.1111/j.1526-4610.2012.02124.xCrossRefPubMed

Tepper SJ, Rapoport AM, Sheftell FD (2002) Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 59:1084–1088. https://doi.org/10.1001/archneur.59.7.1084CrossRefPubMed

MaassenVanDenBrink A, van den Broek RW, de Vries R et al (2000) Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55:1524–1530. https://doi.org/10.1212/wnl.55.10.1524CrossRefPubMed

Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM et al (2018) Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther 186:88–97. https://doi.org/10.1016/j.pharmthera.2018.01.005CrossRefPubMed

Classey JD, Bartsch T, Goadsby PJ (2010) Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: Relevance to the selective anti-migraine effect of triptans. Brain Res 1361:76–85. https://doi.org/10.1016/j.brainres.2010.09.004CrossRefPubMed

Vila-Pueyo M (2018) Targeted 5-HT _1F therapies for migraine. Neurotherapeutics 15:291–303. https://doi.org/10.1007/s13311-018-0615-6CrossRefPubMedPubMedCentral

10.

Bouchelet I, Case B, Olivier A et al (2000) No contractile effect for 5-HT1D and 5- HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 129:501–508. https://doi.org/10.1038/sj.bjp.0703081CrossRefPubMedPubMedCentral

11.

Rizzoli PB (2014) Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat 10:547–552. https://doi.org/10.2147/NDT.S25531CrossRefPubMedPubMedCentral

12.

Durham PL (2006) Calcitonin gene-related peptide (CGRP) and migraine. Headache 46:S3-8. https://doi.org/10.1111/j.1526-4610.2006.00483.xCrossRefPubMedPubMedCentral

13.

McCulloch J, Uddman R, Kingman TA et al (1986) Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A 83:5731–5735. https://doi.org/10.1073/pnas.83.15.5731CrossRefPubMedPubMedCentral

14.

Hoffmann J, Goadsby PJ (2014) Emerging targets in migraine. CNS Drugs 28:11–17. https://doi.org/10.1007/s40263-013-0126-2CrossRefPubMed

15.

Lanfumey L, Hamon M (2004) 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 3:1–10. https://doi.org/10.2174/1568007043482570CrossRefPubMed

16.

Curto M, Cipolla F, Cisale GY et al (2020) Profiling lasmiditan as a treatment option for migraine. Expert Opin Pharmacother 21:147–153. https://doi.org/10.1080/14656566.2019.1694004CrossRefPubMed

17.

Nilsson T, Longmore J, Shaw D et al (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 372:49–56. https://doi.org/10.1016/s0014-2999(99)00114-4CrossRefPubMed

18.

Nelson DL, Phebus LA, Johnson KW et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30:1159–1169. https://doi.org/10.1177/0333102410370873CrossRefPubMed

19.

FDA Approved Drugs: Reyvow (2019).

20.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s0001b1.pdf

21.

Lamb YN (2019) Lasmiditan: first approval. Drugs 79:1989–1996. https://doi.org/10.1007/s40265-019-01225-7CrossRefPubMed

22.

Capi M, De Angelis V, De Bernardini D et al (2021) CGRP receptor antagonists and 5-HT1F receptor agonist in the treatment of migraine. J Clin Med 10:1429. https://doi.org/10.3390/jcm10071429CrossRefPubMedPubMedCentral

23.

ClinicalTrials.gov (2019) Lasmiditan compared to placebo in the acute treatment of migraine: (SAMURAI). NCT02439320. (Ed.^(Eds) (2019)

24.

ClinicalTrials.gov (2019) Three doses of lasmiditan (50 mg, 100 mg and 200 mg) compared to placebo in the acute treatment of migraine (SPARTAN). NCT02605174. (Ed.^(Eds) (2019)

25.

Goadsby P, Wietecha L, Dennehy E et al (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142:1894–1904. https://doi.org/10.1093/brain/awz134CrossRefPubMedPubMedCentral

26.

Loo LS, Plato BM, Turner IM et al (2019) Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol 19:191. https://doi.org/10.1186/s12883-019-1420-5CrossRefPubMedPubMedCentral

27.

Brandes JL, Klise S, Krege JH et al (2019) Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 39:1343–1357. https://doi.org/10.1177/0333102419864132CrossRefPubMedPubMedCentral

28.

Ashina M, Reuter U, Smith T et al (2021) Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia 41:294–304. https://doi.org/10.1177/0333102421989232CrossRefPubMedPubMedCentral

29.

Gu P, Chen C, Wu Q et al (2021) The effect and safety of 5-HT _1F receptor agonist lasmiditan on migraine: a systematic review and meta-analysis. Biomed Res Int 7:6663591. https://doi.org/10.1155/2021/6663591CrossRef

30.

Ferrari MD, Färkkilä M, Reuter U et al (2010) Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia 30:1170–1178. https://doi.org/10.1177/0333102410375512CrossRefPubMed

31.

Johnston K, Popoff E, Deighton A et al (2022) Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Outcomes Res 22:155–166. https://doi.org/10.1080/14737167.2021.1945444CrossRefPubMed

32.

Ferrari MD, Roon KI, Lipton RB et al (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668–1675. https://doi.org/10.1016/S0140-6736(01)06711-3CrossRefPubMed

33.

Färkkilä M, Diener HC, Géraud G et al (2012) Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 11:405–413. https://doi.org/10.1016/S1474-4422(12)70047-9CrossRefPubMed

34.

Lipton RB, Lombard L, Ruff DD et al (2020) Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. J Headache Pain 21:20. https://doi.org/10.1186/s10194-020-01088-4CrossRefPubMedPubMedCentral

35.

Agboola F, Atlas SJ, Touchette DR, et al (2020) The effectiveness and value of novel acute treatments for migraine. J Manag Care Spec Pharm. 26(11):1456–1462.https://doi.org/10.18553/jmcp.2020.26.11.1456

36.

Tsai M, Nery ESM, Kerr L et al (2021) Pharmacokinetics, safety, and tolerability of lasmiditan in pediatric patients with migraine. Clin Pharmacokinet 60:819–828. https://doi.org/10.1007/s40262-020-00966-zCrossRefPubMedPubMedCentral

37.

ClinicalTrials.gov (2020) A study of lasmiditan (LY573144) in children aged 6 to 17 with migraine. NCT03988088. (Ed.^(Eds) (2020)

38.

Tassorelli C, Bragg S, Krege JH et al (2021) Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine. J Headache Pain 22:132. https://doi.org/10.1186/s10194-021-01343-2CrossRefPubMedPubMedCentral

39.

Lucaites VL, Krushinski JH, Schaus JM et al (2005) [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn-Schmiedeberg’s Arch Pharmacol 371:178–184. https://doi.org/10.1007/s00210-005-1036-8CrossRef

40.

Yang CP, Liang CS, Chang CM et al (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4:e2128544. https://doi.org/10.1001/jamanetworkopen.2021.28544CrossRefPubMedPubMedCentral

41.

Hou M, Xing H, Li C et al (2020) Short-term efficacy and safety of lasmiditan, a novel 5-HT _1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. J Headache Pain 21:66. https://doi.org/10.1186/s10194-020-01138-xCrossRefPubMedPubMedCentral

42.

Pearlman EM, Wilbraham D, Dennehy EB et al (2020) Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol 35:e2732. https://doi.org/10.1002/hup.2732CrossRefPubMedPubMedCentral

43.

Reuter U, Israel H, Neeb L (2015) The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord 8:46–54. https://doi.org/10.1177/1756285614562419CrossRefPubMedPubMedCentral

44.

ClinicalTrials.gov (2020) A study of lasmiditan (LY573144) treatment in children aged 6 to 17 with migraine (PIONEER-PEDS1). NCT04396236. (Ed.^(Eds) (2020)

45.

ClinicalTrials.gov (2020) A 12-month study of lasmiditan (LY573144) treatment in children aged 6 to 17 with migraine (PIONEER-PEDS2). NCT04396574. (Ed.^(Eds) (2020)

46.

Tfelt-Hansen PC, Pihl T, Hougaard A et al (2014) Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs 23:375–385. https://doi.org/10.1517/13543784.2014.861817CrossRefPubMed

Title: Ditans: a new prospective for the therapy of migraine attack?
Authors: Giovanna Viticchi
Lorenzo Falsetti
Mauro Silvestrini
Marco Bartolini
Publication date: 11-07-2022
Publisher: Springer International Publishing
Keywords: Migraine
Triptan Drugs
Published in: Neurological Sciences / Issue 9/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06260-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ditans: a new prospective for the therapy of migraine attack?

Abstract

Introduction

Materials and methods

Results

Discussion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Discussion

Please log in to get access to this content

Other articles of this Issue 9/2022

Anti-seizure medication treatment and outcomes in acute ischemic stroke patients undergoing continuous EEG monitoring

Myelodysplastic syndrome in an alemtuzumab-treated multiple sclerosis patient

The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients

Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort

Addressing the cost of chronic and episodic migraine and its main drivers: a short-term longitudinal analysis from a third-level Italian center

Global and local shape features of the hippocampus based on Laplace–Beltrami eigenvalues and eigenfunctions: a potential application in the lateralization of temporal lobe epilepsy